Editors' ChoiceNeurodegenerative Disease A QuICR test to diagnose Parkinson’s disease Albert A. DavisDepartment of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA. Email: albert.a.davis{at}wustl.edu See allHide authors and affiliations Science Translational Medicine 13 Jan 2021:Vol. 13, Issue 576, eabg1761DOI: 10.1126/scitranslmed.abg1761 Albert A. Davis Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA. Email: Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: albert.a.davis@wustl.edu Article Info & Metrics eLetters Article Information vol. 13 no. 576 DOI: https://doi.org/10.1126/scitranslmed.abg1761 Published By: American Association for the Advancement of Science Print ISSN: 1946-6234 Online ISSN: 1946-6242 History: . Copyright & Usage: Copyright © 2021, American Association for the Advancement of Science Author Information Albert A. DavisDepartment of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA. Email: albert.a.davis{at}wustl.edu Altmetric Article usage Article lifetimeLast 6 monthsThis monthArticle usage: January 2021 to January 2021 AbstractFullPdf Jan 202110516393 View Full Text
A QuICR test to diagnose Parkinson’s disease By Albert A. Davis Science Translational Medicine13 Jan 2021 Refined conditions permit rapid detection of proteopathic α-synuclein seeds in cerebrospinal fluid from patients with Parkinson’s disease.
A QuICR test to diagnose Parkinson’s disease By Albert A. Davis Science Translational Medicine13 Jan 2021 Refined conditions permit rapid detection of proteopathic α-synuclein seeds in cerebrospinal fluid from patients with Parkinson’s disease.